Synthetic test data. This release was generated from a synthetic store to exercise the pipeline. Nothing in it is a report from a person.
Release
EXAMPLE-SYNTHETIC
Computed on 2026-12-31 under release specification v1.0 and schema 1.0. Counts are as of that date and leave out every excluded report. Tables update in batches of at least five reports; a table waiting for its batch is shown unchanged and says which release computed it.
- Reports committed
- 1,500
- Excluded
- 0 (none) — list
- Not excluded
- 1,500
- Merkle root
49d08c112ca6b8914c888610f79d093be7ede651300ec2d2757216bce51ec87b
over 1,500 leaves — leaf list- Files
- release.json (hash of every file) · how we count reports
- Witness
- not yet witnessed
Read every figure with these in mind. The people who report here chose to; they are not a sample of anyone. They reported from memory, after the fact, knowing what they took and what they hoped for. Two vials sold under the same name can contain different things. Nothing here is a clinical trial, a rate, a comparison, or evidence that anything works or is safe. Where most people report no change, that is the most trustworthy number on the page — every bias above pushes the other way.
Counts by compound
Compounds appear in the fixed order of the schema, never ordered by any result. What is shown for each depends only on how many reports it has.
| Compound | Reports | Shown |
|---|---|---|
| Retatrutide | 43 | count, route and source |
| Tirzepatide | 36 | count, route and source |
| Semaglutide | 35 | count, route and source |
| Cagrilintide | 28 | count, route and source |
| Mazdutide | 30 | count, route and source |
| Survodutide | 33 | count, route and source |
| Liraglutide | 22 | count, route and source |
| Compound | Reports | Shown |
|---|---|---|
| CJC-1295 (no DAC) / ipamorelin blend | 16 | count, route and source |
| Ipamorelin | 18 | count, route and source |
| Tesamorelin | 21 | count, route and source |
| MK-677 (ibutamoren) | 10 | count, route and source |
| Somatropin (HGH) | 12 | count, route and source |
| CJC-1295 without DAC (Mod GRF 1-29) | 12 | count, route and source |
| Sermorelin | 19 | count, route and source |
| CJC-1295 with DAC | 11 | count, route and source |
| GHRP-6 | 14 | count, route and source |
| GHRP-2 (pralmorelin) | 17 | count, route and source |
| Hexarelin | fewer than 10 reports — not enough to show | fewer than 10 reports |
| Compound | Reports | Shown |
|---|---|---|
| GHK-Cu | 272 | plus percentages and effect timing |
| BPC-157 | 11 | count, route and source |
| TB-500 | 10 | count, route and source |
| BPC-157 + TB-500 blend (Wolverine stack) | fewer than 10 reports — not enough to show | fewer than 10 reports |
| KPV | 12 | count, route and source |
| LL-37 | 11 | count, route and source |
| ARA-290 (cibinetide) | 10 | count, route and source |
| Compound | Reports | Shown |
|---|---|---|
| Oxytocin (intranasal) | 62 | all one-way tables |
| DSIP (delta sleep-inducing peptide) | 54 | all one-way tables |
| Semax | 21 | count, route and source |
| Selank | 29 | count, route and source |
| Cerebrolysin | 16 | count, route and source |
| Dihexa | 19 | count, route and source |
| P21 (P021) | 20 | count, route and source |
| Pinealon | 11 | count, route and source |
| Compound | Reports | Shown |
|---|---|---|
| AOD-9604 | 10 | count, route and source |
| NAD+ (injectable) | 13 | count, route and source |
| MOTS-c | fewer than 10 reports — not enough to show | fewer than 10 reports |
| Epitalon | 10 | count, route and source |
| 5-amino-1MQ | 11 | count, route and source |
| Glutathione (injectable) | 14 | count, route and source |
| Thymosin alpha-1 | fewer than 10 reports — not enough to show | fewer than 10 reports |
| Tesofensine | fewer than 10 reports — not enough to show | fewer than 10 reports |
| SS-31 (elamipretide) | fewer than 10 reports — not enough to show | fewer than 10 reports |
| Humanin | 11 | count, route and source |
| SLU-PP-332 | 10 | count, route and source |
| FOXO4-DRI | fewer than 10 reports — not enough to show | fewer than 10 reports |
| Compound | Reports | Shown |
|---|---|---|
| PT-141 (bremelanotide) | 137 | plus outcome by goal |
| Melanotan II | 89 | all one-way tables |
| Kisspeptin-10 | 86 | all one-way tables |
| Melanotan I (afamelanotide) | 50 | all one-way tables |
| Gonadorelin | 47 | count, route and source |
Other (not listed): 27 reports. Counted, never broken out.
By compound
Retatrutide — 43 reports · count, route and source
Retatrutide — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 43 |
| All | 43 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Retatrutide — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 6 |
| Telehealth or clinic (compounded) | 6 |
| Domestic research-chemical vendor | 10 |
| Overseas vendor | 13 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 43 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Tirzepatide — 36 reports · count, route and source
Tirzepatide — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 23 |
| Oral / sublingual / troche | 13 |
| All | 36 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Tirzepatide — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 7 |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 10 |
| Overseas vendor | 7 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 36 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Semaglutide — 35 reports · count, route and source
Semaglutide — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 26 |
| Oral / sublingual / troche | 9 |
| All | 35 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Semaglutide — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | 8 |
| Domestic research-chemical vendor | 11 |
| Overseas vendor | 6 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 35 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Cagrilintide — 28 reports · count, route and source
Cagrilintide — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 28 |
| All | 28 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Cagrilintide — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 5 |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 16 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 28 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Mazdutide — 30 reports · count, route and source
Mazdutide — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 30 |
| All | 30 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Mazdutide — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | 5 |
| Domestic research-chemical vendor | 11 |
| Overseas vendor | 7 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 30 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Survodutide — 33 reports · count, route and source
Survodutide — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 33 |
| All | 33 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Survodutide — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 5 |
| Telehealth or clinic (compounded) | 7 |
| Domestic research-chemical vendor | 9 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 33 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Liraglutide — 22 reports · count, route and source
Liraglutide — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 22 |
| All | 22 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Liraglutide — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 6 |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 8 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 22 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
CJC-1295 (no DAC) / ipamorelin blend — 16 reports · count, route and source
CJC-1295 (no DAC) / ipamorelin blend — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 16 |
| All | 16 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
CJC-1295 (no DAC) / ipamorelin blend — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 5 |
| Overseas vendor | 5 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 16 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Ipamorelin — 18 reports · count, route and source
Ipamorelin — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 18 |
| All | 18 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Ipamorelin — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | 6 |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 18 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Tesamorelin — 21 reports · count, route and source
Tesamorelin — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 21 |
| All | 21 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Tesamorelin — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | 5 |
| Domestic research-chemical vendor | 10 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 21 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
MK-677 (ibutamoren) — 10 reports · count, route and source
MK-677 (ibutamoren) — route — as a table
| Answer | Reports |
|---|---|
| Oral / sublingual / troche | 10 |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
MK-677 (ibutamoren) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Somatropin (HGH) — 12 reports · count, route and source
Somatropin (HGH) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | not shown |
| Intramuscular injection | not shown |
| All | 12 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Somatropin (HGH) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | 5 |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 12 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
CJC-1295 without DAC (Mod GRF 1-29) — 12 reports · count, route and source
CJC-1295 without DAC (Mod GRF 1-29) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 12 |
| All | 12 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
CJC-1295 without DAC (Mod GRF 1-29) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 12 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Sermorelin — 19 reports · count, route and source
Sermorelin — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 19 |
| All | 19 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Sermorelin — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 6 |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | 6 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 19 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
CJC-1295 with DAC — 11 reports · count, route and source
CJC-1295 with DAC — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 11 |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
CJC-1295 with DAC — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHRP-6 — 14 reports · count, route and source
GHRP-6 — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 14 |
| All | 14 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHRP-6 — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 14 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHRP-2 (pralmorelin) — 17 reports · count, route and source
GHRP-2 (pralmorelin) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 17 |
| All | 17 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHRP-2 (pralmorelin) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 5 |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 6 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 17 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — 272 reports · plus percentages and effect timing
GHK-Cu — route — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Topical / transdermal | 70.6% (65–76) · 192 |
| Subcutaneous injection | 29.4% (24–35) · 80 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — source channel — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Retail pharmacy (brand product, prescription) | 4.8% (3–8) · 13 |
| Compounding pharmacy | 14.0% (10–19) · 38 |
| Telehealth or clinic (compounded) | 19.9% (16–25) · 54 |
| Domestic research-chemical vendor | 28.7% (24–34) · 78 |
| Overseas vendor | 22.1% (18–27) · 60 |
| From another person | 5.1% (3–9) · 14 |
| Don't know | 3.7% (2–7) · 10 |
| Other (not listed) | 1.8% (1–4) · 5 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — what people took it for — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Skin appearance / fine lines / anti-aging look | 37.1% (32–43) · 101 |
| Hair regrowth or thicker hair | 16.2% (12–21) · 44 |
| Healing wounds, scars, acne marks or stretch marks | 14.7% (11–19) · 40 |
| More even skin tone | 10.7% (8–15) · 29 |
| Healing a tendon, ligament, muscle or joint injury | 11.4% (8–16) · 31 |
| General longevity / anti-aging | 5.1% (3–9) · 14 |
| Other (not listed) | 4.8% (3–8) · 13 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — starting dose — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Topical only (no injection) | 25.4% (21–31) · 69 |
| Under 1 mg per day injected | 31.6% (26–37) · 86 |
| 1 to 2 mg per day injected | 22.1% (18–27) · 60 |
| 2 to 4 mg per day injected | 12.9% (9–17) · 35 |
| Over 4 mg per day injected | 8.1% (5–12) · 22 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — current or final dose — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Topical only (no injection) | 19.1% (15–24) · 52 |
| Under 1 mg per day injected | 29.8% (25–36) · 81 |
| 1 to 2 mg per day injected | 22.4% (18–28) · 61 |
| 2 to 4 mg per day injected | 16.9% (13–22) · 46 |
| Over 4 mg per day injected | 11.8% (9–16) · 32 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — frequency — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Once a day | 39.7% (34–46) · 108 |
| 5 days on / 2 days off | 20.2% (16–25) · 55 |
| 2–3 times a week | 12.9% (9–17) · 35 |
| About once a week | 9.6% (7–14) · 26 |
| More than once a day | 7.4% (5–11) · 20 |
| In cycles (weeks on, weeks off) | 6.2% (4–10) · 17 |
| Other (not listed) | 4.0% (2–7) · 11 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — duration — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Under 2 weeks | 9.9% (7–14) · 27 |
| 2 to 4 weeks | 21.3% (17–27) · 58 |
| 1 to 3 months | 32.4% (27–38) · 88 |
| 3 to 6 months | 19.1% (15–24) · 52 |
| 6 to 12 months | 10.3% (7–15) · 28 |
| Over 12 months | 7.0% (5–11) · 19 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — independent purity testing — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| No, did not test | 70.2% (65–75) · 191 |
| Yes — result matched the label | 17.6% (14–23) · 48 |
| Yes — result did not match the label | 2.9% (2–6) · 8 |
| Yes — unsure how to read the result | 4.0% (2–7) · 11 |
| Don't know | 5.1% (3–9) · 14 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — outcome by goal — as a table
| No change | Slight improvement | Moderate improvement | Large improvement | n | |
|---|---|---|---|---|---|
| Skin appearance / fine lines / anti-aging look | 36.6% (28–46) · 37 | 26.7% (19–36) · 27 | 29.7% (22–39) · 30 | 6.9% (3–14) · 7 | 101 |
| Hair regrowth or thicker hair | 11 | 14 | 10 | 9 | 44 |
| Healing wounds, scars, acne marks or stretch marks | 16 | 14 | not shown | not shown | 40 |
| More even skin tone | 13 | 6 | not shown | not shown | 29 |
| Healing a tendon, ligament, muscle or joint injury | 13 | 8 | not shown | not shown | 31 |
| General longevity / anti-aging | fewer than 20 reports | ||||
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — side effects reported — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| No side effects reported | 49.6% (44–56) · 135 |
| Headache | 5.5% (3–9) · 15 |
| Nausea | 9.2% (6–13) · 25 |
| Vomiting | 4.4% (3–8) · 12 |
| Dizziness or lightheadedness | 3.3% (2–6) · 9 |
| Fatigue / low energy | 5.5% (3–9) · 15 |
| Trouble sleeping | 4.4% (3–8) · 12 |
| Vivid dreams | 4.8% (3–8) · 13 |
| Flushing or feeling warm | 6.2% (4–10) · 17 |
| Anxiety, restlessness or feeling wired | 4.8% (3–8) · 13 |
| Low mood or irritability | 5.1% (3–9) · 14 |
| Appetite change | 5.9% (4–9) · 16 |
| Injection-site reaction (redness, itching, lump, bruising) | 1.8% (1–4) · 5 |
| Nasal irritation, burning or sneezing | not shown |
| Effect faded with repeated use | 2.2% (1–5) · 6 |
| No noticeable effect at all | 3.3% (2–6) · 9 |
| Blue-green staining or residue on skin | 2.6% (1–5) · 7 |
| Skin irritation, rash, hives or breakouts | 6.6% (4–10) · 18 |
| Hair shedding | 4.0% (2–7) · 11 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — nausea: when it started — as a table
| In the first few days | In the first 2 weeks | Between 2 and 6 weeks | After 6 weeks | Not sure | n | |
|---|---|---|---|---|---|---|
| When it started | 5 | 7 | not shown | not shown | 8 | 25 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — nausea: after stopping — as a table
| Went away after stopping | Did not go away after stopping | Haven't stopped | Not sure | n | |
|---|---|---|---|---|---|
| After stopping | 12 | not shown | 6 | not shown | 25 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — still taking, stopped, or finished — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Still taking it | 38.6% (33–45) · 105 |
| Finished a planned course | 16.5% (13–21) · 45 |
| Stopped before I planned to | 44.9% (39–51) · 122 |
| All | 272 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
GHK-Cu — main reason for stopping — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Got what I wanted from it | 25.4% (19–34) · 31 |
| It wasn't doing anything | 33.6% (26–42) · 41 |
| Side effects | 7.4% (4–13) · 9 |
| Cost | 9.8% (6–16) · 12 |
| Couldn't get more | 9.8% (6–16) · 12 |
| Worried about safety | 7.4% (4–13) · 9 |
| Other (not listed) | 6.6% (3–12) · 8 |
| All | 122 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
BPC-157 — 11 reports · count, route and source
BPC-157 — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 6 |
| Oral / sublingual / troche | not shown |
| Nasal spray / drops | not shown |
| Intramuscular injection | not shown |
| Topical / transdermal | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
BPC-157 — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
TB-500 — 10 reports · count, route and source
TB-500 — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 5 |
| Intramuscular injection | not shown |
| Oral / sublingual / troche | not shown |
| Nasal spray / drops | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
TB-500 — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
KPV — 12 reports · count, route and source
KPV — route — as a table
| Answer | Reports |
|---|---|
| Oral / sublingual / troche | 7 |
| Subcutaneous injection | not shown |
| Nasal spray / drops | not shown |
| Topical / transdermal | not shown |
| All | 12 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
KPV — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 5 |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 12 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
LL-37 — 11 reports · count, route and source
LL-37 — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 5 |
| Intramuscular injection | not shown |
| Nasal spray / drops | not shown |
| Topical / transdermal | not shown |
| Oral / sublingual / troche | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
LL-37 — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
ARA-290 (cibinetide) — 10 reports · count, route and source
ARA-290 (cibinetide) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 10 |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
ARA-290 (cibinetide) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — 62 reports · all one-way tables
Oxytocin (intranasal) — route — as a table
| Answer | Reports |
|---|---|
| Nasal spray / drops | 32 |
| Oral / sublingual / troche | 18 |
| Subcutaneous injection | 12 |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 8 |
| Telehealth or clinic (compounded) | 8 |
| Domestic research-chemical vendor | 21 |
| Overseas vendor | 16 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — what people took it for — as a table
| Answer | Reports |
|---|---|
| Feeling calmer or more at ease socially | 20 |
| Closer bonding or intimacy with a partner | 18 |
| More intense arousal or orgasm | 13 |
| Better mood / lifting depression | not shown |
| Less anxiety or stress | not shown |
| Deeper, more restorative sleep | not shown |
| Other (not listed) | not shown |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — starting dose — as a table
| Answer | Reports |
|---|---|
| Under 10 IU per dose | 13 |
| 10 to under 20 IU per dose | 17 |
| 20 to under 30 IU per dose | 20 |
| 30 to 50 IU per dose | 6 |
| Over 50 IU per dose | 6 |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — current or final dose — as a table
| Answer | Reports |
|---|---|
| Under 10 IU per dose | 10 |
| 10 to under 20 IU per dose | 11 |
| 20 to under 30 IU per dose | 25 |
| 30 to 50 IU per dose | 10 |
| Over 50 IU per dose | 6 |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — frequency — as a table
| Answer | Reports |
|---|---|
| As needed / on demand | 25 |
| Once a day | 11 |
| More than once a day | 7 |
| 2–3 times a week | 9 |
| In cycles (weeks on, weeks off) | 5 |
| Other (not listed) | 5 |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — duration — as a table
| Answer | Reports |
|---|---|
| Under 2 weeks | not shown |
| 2 to 4 weeks | 13 |
| 1 to 3 months | 21 |
| 3 to 6 months | not shown |
| 6 to 12 months | 8 |
| Over 12 months | 11 |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — independent purity testing — as a table
| Answer | Reports |
|---|---|
| No, did not test | 41 |
| Yes — result matched the label | 10 |
| Yes — result did not match the label | 5 |
| Yes — unsure how to read the result | not shown |
| Don't know | not shown |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — side effects reported — as a table
| Answer | Reports |
|---|---|
| No side effects reported | 34 |
| Headache | not shown |
| Nausea | not shown |
| Vomiting | not shown |
| Dizziness or lightheadedness | not shown |
| Fatigue / low energy | not shown |
| Trouble sleeping | not shown |
| Vivid dreams | not shown |
| Flushing or feeling warm | not shown |
| Anxiety, restlessness or feeling wired | not shown |
| Low mood or irritability | not shown |
| Appetite change | not shown |
| Injection-site reaction (redness, itching, lump, bruising) | not shown |
| Nasal irritation, burning or sneezing | not shown |
| Effect faded with repeated use | not shown |
| No noticeable effect at all | not shown |
| Feeling weepy or emotionally raw | not shown |
| Cramping (women) | not shown |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — still taking, stopped, or finished — as a table
| Answer | Reports |
|---|---|
| Still taking it | 33 |
| Finished a planned course | 7 |
| Stopped before I planned to | 22 |
| All | 62 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Oxytocin (intranasal) — main reason for stopping — as a table
| Answer | Reports |
|---|---|
| Got what I wanted from it | 7 |
| It wasn't doing anything | 6 |
| Side effects | not shown |
| Cost | not shown |
| Couldn't get more | not shown |
| Worried about safety | not shown |
| Other (not listed) | not shown |
| All | 22 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — 54 reports · all one-way tables
DSIP (delta sleep-inducing peptide) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 35 |
| Nasal spray / drops | 19 |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 9 |
| Telehealth or clinic (compounded) | 12 |
| Domestic research-chemical vendor | 13 |
| Overseas vendor | 7 |
| From another person | 5 |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — what people took it for — as a table
| Answer | Reports |
|---|---|
| Falling asleep faster | 21 |
| Deeper, more restorative sleep | 17 |
| More daily energy, less fatigue | 9 |
| Less anxiety or stress | not shown |
| Other (not listed) | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — starting dose — as a table
| Answer | Reports |
|---|---|
| Under 100 mcg per dose | 15 |
| 100 to under 200 mcg per dose | 19 |
| 200 to under 400 mcg per dose | 12 |
| 400 mcg to 1 mg per dose | not shown |
| Over 1 mg per dose | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — current or final dose — as a table
| Answer | Reports |
|---|---|
| Under 100 mcg per dose | 13 |
| 100 to under 200 mcg per dose | 16 |
| 200 to under 400 mcg per dose | 13 |
| 400 mcg to 1 mg per dose | not shown |
| Over 1 mg per dose | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — frequency — as a table
| Answer | Reports |
|---|---|
| Once a day | 28 |
| 2–3 times a week | 8 |
| As needed / on demand | not shown |
| In cycles (weeks on, weeks off) | 8 |
| Other (not listed) | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — duration — as a table
| Answer | Reports |
|---|---|
| Under 2 weeks | 6 |
| 2 to 4 weeks | 8 |
| 1 to 3 months | 15 |
| 3 to 6 months | 17 |
| 6 to 12 months | not shown |
| Over 12 months | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — independent purity testing — as a table
| Answer | Reports |
|---|---|
| No, did not test | 34 |
| Yes — result matched the label | 9 |
| Yes — result did not match the label | not shown |
| Yes — unsure how to read the result | not shown |
| Don't know | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — side effects reported — as a table
| Answer | Reports |
|---|---|
| No side effects reported | 26 |
| Headache | not shown |
| Nausea | not shown |
| Vomiting | 5 |
| Dizziness or lightheadedness | not shown |
| Fatigue / low energy | not shown |
| Trouble sleeping | not shown |
| Vivid dreams | not shown |
| Flushing or feeling warm | not shown |
| Anxiety, restlessness or feeling wired | not shown |
| Low mood or irritability | not shown |
| Appetite change | 6 |
| Injection-site reaction (redness, itching, lump, bruising) | not shown |
| Nasal irritation, burning or sneezing | not shown |
| Effect faded with repeated use | 5 |
| No noticeable effect at all | not shown |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — still taking, stopped, or finished — as a table
| Answer | Reports |
|---|---|
| Still taking it | 16 |
| Finished a planned course | 6 |
| Stopped before I planned to | 32 |
| All | 54 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
DSIP (delta sleep-inducing peptide) — main reason for stopping — as a table
| Answer | Reports |
|---|---|
| Got what I wanted from it | 5 |
| It wasn't doing anything | 12 |
| Side effects | not shown |
| Cost | not shown |
| Couldn't get more | 5 |
| Worried about safety | not shown |
| Other (not listed) | not shown |
| All | 32 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Semax — 21 reports · count, route and source
Semax — route — as a table
| Answer | Reports |
|---|---|
| Nasal spray / drops | 13 |
| Subcutaneous injection | 8 |
| All | 21 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Semax — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | 6 |
| Domestic research-chemical vendor | 5 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 21 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Selank — 29 reports · count, route and source
Selank — route — as a table
| Answer | Reports |
|---|---|
| Nasal spray / drops | 18 |
| Subcutaneous injection | 11 |
| All | 29 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Selank — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | 10 |
| Domestic research-chemical vendor | 9 |
| Overseas vendor | 5 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 29 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Cerebrolysin — 16 reports · count, route and source
Cerebrolysin — route — as a table
| Answer | Reports |
|---|---|
| Intramuscular injection | 12 |
| Subcutaneous injection | not shown |
| Intravenous (clinic) | not shown |
| All | 16 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Cerebrolysin — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 5 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 16 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Dihexa — 19 reports · count, route and source
Dihexa — route — as a table
| Answer | Reports |
|---|---|
| Oral / sublingual / troche | 9 |
| Topical / transdermal | not shown |
| Subcutaneous injection | 5 |
| Nasal spray / drops | not shown |
| All | 19 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Dihexa — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 10 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 19 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
P21 (P021) — 20 reports · count, route and source
P21 (P021) — route — as a table
| Answer | Reports |
|---|---|
| Nasal spray / drops | 13 |
| Subcutaneous injection | 7 |
| All | 20 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
P21 (P021) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 7 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 20 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Pinealon — 11 reports · count, route and source
Pinealon — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 9 |
| Nasal spray / drops | not shown |
| Oral / sublingual / troche | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Pinealon — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
AOD-9604 — 10 reports · count, route and source
AOD-9604 — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 5 |
| Oral / sublingual / troche | not shown |
| Intramuscular injection | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
AOD-9604 — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
NAD+ (injectable) — 13 reports · count, route and source
NAD+ (injectable) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 6 |
| Intramuscular injection | not shown |
| Intravenous (clinic) | not shown |
| Nasal spray / drops | not shown |
| Oral / sublingual / troche | not shown |
| All | 13 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
NAD+ (injectable) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | 6 |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 13 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Epitalon — 10 reports · count, route and source
Epitalon — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | not shown |
| Intramuscular injection | not shown |
| Nasal spray / drops | not shown |
| Oral / sublingual / troche | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Epitalon — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
5-amino-1MQ — 11 reports · count, route and source
5-amino-1MQ — route — as a table
| Answer | Reports |
|---|---|
| Oral / sublingual / troche | not shown |
| Subcutaneous injection | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
5-amino-1MQ — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Glutathione (injectable) — 14 reports · count, route and source
Glutathione (injectable) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 5 |
| Intramuscular injection | not shown |
| Intravenous (clinic) | not shown |
| Nasal spray / drops | not shown |
| All | 14 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Glutathione (injectable) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | 6 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 14 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Humanin — 11 reports · count, route and source
Humanin — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 11 |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Humanin — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 11 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
SLU-PP-332 — 10 reports · count, route and source
SLU-PP-332 — route — as a table
| Answer | Reports |
|---|---|
| Oral / sublingual / troche | not shown |
| Subcutaneous injection | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
SLU-PP-332 — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | not shown |
| Telehealth or clinic (compounded) | not shown |
| Domestic research-chemical vendor | not shown |
| Overseas vendor | not shown |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 10 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — 137 reports · plus outcome by goal
PT-141 (bremelanotide) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 97 |
| Nasal spray / drops | 40 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | 12 |
| Compounding pharmacy | 20 |
| Telehealth or clinic (compounded) | 23 |
| Domestic research-chemical vendor | 37 |
| Overseas vendor | 31 |
| From another person | 8 |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — what people took it for — as a table
| Answer | Reports |
|---|---|
| Stronger sexual desire / libido | 59 |
| Firmer or more reliable erections | 30 |
| Add-on when ED medication is not enough | 24 |
| More intense arousal or orgasm | 15 |
| Other (not listed) | 9 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — starting dose — as a table
| Answer | Reports |
|---|---|
| Under 0.5 mg per dose | 25 |
| 0.5 to under 1 mg per dose | 48 |
| 1 to under 1.5 mg per dose | 36 |
| 1.5 to 2 mg per dose | 17 |
| Over 2 mg per dose | 11 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — current or final dose — as a table
| Answer | Reports |
|---|---|
| Under 0.5 mg per dose | 25 |
| 0.5 to under 1 mg per dose | 28 |
| 1 to under 1.5 mg per dose | 39 |
| 1.5 to 2 mg per dose | 29 |
| Over 2 mg per dose | 16 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — frequency — as a table
| Answer | Reports |
|---|---|
| As needed / on demand | 58 |
| 2–3 times a week | 30 |
| Once a day | 19 |
| In cycles (weeks on, weeks off) | 12 |
| Other (not listed) | 18 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — duration — as a table
| Answer | Reports |
|---|---|
| Under 2 weeks | 12 |
| 2 to 4 weeks | 25 |
| 1 to 3 months | 36 |
| 3 to 6 months | 27 |
| 6 to 12 months | 20 |
| Over 12 months | 17 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — independent purity testing — as a table
| Answer | Reports |
|---|---|
| No, did not test | 94 |
| Yes — result matched the label | 16 |
| Yes — result did not match the label | 12 |
| Yes — unsure how to read the result | 7 |
| Don't know | 8 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — outcome by goal — as a table
| No change | Slight improvement | Moderate improvement | Large improvement | n | |
|---|---|---|---|---|---|
| Stronger sexual desire / libido | 24 | 15 | 15 | 5 | 59 |
| Firmer or more reliable erections | 11 | 12 | not shown | not shown | 30 |
| Add-on when ED medication is not enough | not shown | 6 | 9 | not shown | 24 |
| More intense arousal or orgasm | fewer than 20 reports | ||||
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — side effects reported — as a table
| Answer | Reports |
|---|---|
| No side effects reported | 54 |
| Headache | 8 |
| Nausea | 10 |
| Vomiting | 7 |
| Dizziness or lightheadedness | 11 |
| Fatigue / low energy | 6 |
| Trouble sleeping | 8 |
| Vivid dreams | not shown |
| Flushing or feeling warm | 5 |
| Anxiety, restlessness or feeling wired | 6 |
| Low mood or irritability | 7 |
| Appetite change | 9 |
| Injection-site reaction (redness, itching, lump, bruising) | 5 |
| Nasal irritation, burning or sneezing | not shown |
| Effect faded with repeated use | 10 |
| No noticeable effect at all | not shown |
| Racing heart, palpitations or higher resting heart rate | 11 |
| New or darkening moles / freckles | 5 |
| Unwanted or prolonged erections | 5 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — still taking, stopped, or finished — as a table
| Answer | Reports |
|---|---|
| Still taking it | 51 |
| Finished a planned course | 22 |
| Stopped before I planned to | 64 |
| All | 137 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
PT-141 (bremelanotide) — main reason for stopping — as a table
| Answer | Reports |
|---|---|
| Got what I wanted from it | 17 |
| It wasn't doing anything | 16 |
| Side effects | 9 |
| Cost | 7 |
| Couldn't get more | 9 |
| Worried about safety | not shown |
| Other (not listed) | not shown |
| All | 64 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — 89 reports · all one-way tables
Melanotan II — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 65 |
| Nasal spray / drops | 24 |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | 9 |
| Compounding pharmacy | 13 |
| Telehealth or clinic (compounded) | 14 |
| Domestic research-chemical vendor | 26 |
| Overseas vendor | 14 |
| From another person | 6 |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — what people took it for — as a table
| Answer | Reports |
|---|---|
| Darker tan with less sun exposure | 37 |
| Tanning without burning / sun sensitivity | 20 |
| Stronger sexual desire / libido | 14 |
| Appetite control / quieting food noise | not shown |
| More even skin tone | 8 |
| Other (not listed) | not shown |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — starting dose — as a table
| Answer | Reports |
|---|---|
| Under 100 mcg per dose | 32 |
| 100 to under 250 mcg per dose | 28 |
| 250 to under 500 mcg per dose | 12 |
| 500 mcg to 1 mg per dose | 9 |
| Over 1 mg per dose | 8 |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — current or final dose — as a table
| Answer | Reports |
|---|---|
| Under 100 mcg per dose | 29 |
| 100 to under 250 mcg per dose | 20 |
| 250 to under 500 mcg per dose | 17 |
| 500 mcg to 1 mg per dose | 12 |
| Over 1 mg per dose | 11 |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — frequency — as a table
| Answer | Reports |
|---|---|
| Once a day | 39 |
| Every other day | 17 |
| 2–3 times a week | 16 |
| About once a week | 11 |
| In cycles (weeks on, weeks off) | not shown |
| Other (not listed) | not shown |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — duration — as a table
| Answer | Reports |
|---|---|
| Under 2 weeks | not shown |
| 2 to 4 weeks | 15 |
| 1 to 3 months | 32 |
| 3 to 6 months | 18 |
| 6 to 12 months | 13 |
| Over 12 months | not shown |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — independent purity testing — as a table
| Answer | Reports |
|---|---|
| No, did not test | 63 |
| Yes — result matched the label | 16 |
| Yes — result did not match the label | not shown |
| Yes — unsure how to read the result | not shown |
| Don't know | not shown |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — side effects reported — as a table
| Answer | Reports |
|---|---|
| No side effects reported | 30 |
| Headache | 7 |
| Nausea | 8 |
| Vomiting | 5 |
| Dizziness or lightheadedness | 6 |
| Fatigue / low energy | not shown |
| Trouble sleeping | 6 |
| Vivid dreams | 7 |
| Flushing or feeling warm | not shown |
| Anxiety, restlessness or feeling wired | not shown |
| Low mood or irritability | not shown |
| Appetite change | 5 |
| Injection-site reaction (redness, itching, lump, bruising) | 5 |
| Nasal irritation, burning or sneezing | not shown |
| Effect faded with repeated use | not shown |
| No noticeable effect at all | not shown |
| Unwanted or prolonged erections | not shown |
| New or darkening moles / freckles | 7 |
| Uneven skin darkening | 5 |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — still taking, stopped, or finished — as a table
| Answer | Reports |
|---|---|
| Still taking it | 40 |
| Finished a planned course | 9 |
| Stopped before I planned to | 40 |
| All | 89 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan II — main reason for stopping — as a table
| Answer | Reports |
|---|---|
| Got what I wanted from it | 7 |
| It wasn't doing anything | 15 |
| Side effects | not shown |
| Cost | 7 |
| Couldn't get more | 6 |
| Worried about safety | not shown |
| Other (not listed) | not shown |
| All | 40 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — 86 reports · all one-way tables
Kisspeptin-10 — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 59 |
| Nasal spray / drops | 27 |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | 6 |
| Compounding pharmacy | 13 |
| Telehealth or clinic (compounded) | 16 |
| Domestic research-chemical vendor | 27 |
| Overseas vendor | 17 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — what people took it for — as a table
| Answer | Reports |
|---|---|
| Higher natural testosterone | 30 |
| Stronger sexual desire / libido | 16 |
| Restoring hormone function after a cycle or TRT | 19 |
| Fertility | 10 |
| Better mood / lifting depression | not shown |
| Other (not listed) | not shown |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — starting dose — as a table
| Answer | Reports |
|---|---|
| Under 50 mcg per dose | 16 |
| 50 to under 100 mcg per dose | 29 |
| 100 to under 250 mcg per dose | 19 |
| 250 to 500 mcg per dose | 11 |
| Over 500 mcg per dose | 11 |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — current or final dose — as a table
| Answer | Reports |
|---|---|
| Under 50 mcg per dose | 15 |
| 50 to under 100 mcg per dose | 21 |
| 100 to under 250 mcg per dose | 21 |
| 250 to 500 mcg per dose | 14 |
| Over 500 mcg per dose | 15 |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — frequency — as a table
| Answer | Reports |
|---|---|
| As needed / on demand | 36 |
| Once a day | 14 |
| Every other day | 17 |
| 2–3 times a week | 8 |
| In cycles (weeks on, weeks off) | 5 |
| Other (not listed) | 6 |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — duration — as a table
| Answer | Reports |
|---|---|
| Under 2 weeks | 7 |
| 2 to 4 weeks | 12 |
| 1 to 3 months | 30 |
| 3 to 6 months | 17 |
| 6 to 12 months | 11 |
| Over 12 months | 9 |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — independent purity testing — as a table
| Answer | Reports |
|---|---|
| No, did not test | 57 |
| Yes — result matched the label | 11 |
| Yes — result did not match the label | 8 |
| Yes — unsure how to read the result | not shown |
| Don't know | not shown |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — side effects reported — as a table
| Answer | Reports |
|---|---|
| No side effects reported | 38 |
| Headache | 5 |
| Nausea | 5 |
| Vomiting | 6 |
| Dizziness or lightheadedness | 6 |
| Fatigue / low energy | not shown |
| Trouble sleeping | not shown |
| Vivid dreams | not shown |
| Flushing or feeling warm | 14 |
| Anxiety, restlessness or feeling wired | not shown |
| Low mood or irritability | 6 |
| Appetite change | 7 |
| Injection-site reaction (redness, itching, lump, bruising) | 6 |
| Nasal irritation, burning or sneezing | not shown |
| Effect faded with repeated use | 5 |
| No noticeable effect at all | not shown |
| Acne or oily skin | not shown |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — still taking, stopped, or finished — as a table
| Answer | Reports |
|---|---|
| Still taking it | 37 |
| Finished a planned course | 9 |
| Stopped before I planned to | 40 |
| All | 86 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Kisspeptin-10 — main reason for stopping — as a table
| Answer | Reports |
|---|---|
| Got what I wanted from it | 13 |
| It wasn't doing anything | 12 |
| Side effects | not shown |
| Cost | not shown |
| Couldn't get more | 7 |
| Worried about safety | not shown |
| Other (not listed) | not shown |
| All | 40 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — 50 reports · all one-way tables
Melanotan I (afamelanotide) — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 50 |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 6 |
| Telehealth or clinic (compounded) | 11 |
| Domestic research-chemical vendor | 16 |
| Overseas vendor | 9 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — what people took it for — as a table
| Answer | Reports |
|---|---|
| Darker tan with less sun exposure | 20 |
| Tanning without burning / sun sensitivity | 13 |
| More even skin tone | 9 |
| Other (not listed) | 8 |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — starting dose — as a table
| Answer | Reports |
|---|---|
| Under 0.5 mg per dose | 10 |
| 0.5 to under 1 mg per dose | 20 |
| 1 to 2 mg per dose | 10 |
| Over 2 mg per dose | 10 |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — current or final dose — as a table
| Answer | Reports |
|---|---|
| Under 0.5 mg per dose | 7 |
| 0.5 to under 1 mg per dose | 12 |
| 1 to 2 mg per dose | 18 |
| Over 2 mg per dose | 13 |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — frequency — as a table
| Answer | Reports |
|---|---|
| Once a day | 14 |
| Every other day | 8 |
| 2–3 times a week | 7 |
| About once a week | 13 |
| In cycles (weeks on, weeks off) | not shown |
| Other (not listed) | not shown |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — duration — as a table
| Answer | Reports |
|---|---|
| Under 2 weeks | 7 |
| 2 to 4 weeks | 8 |
| 1 to 3 months | 18 |
| 3 to 6 months | 11 |
| 6 to 12 months | not shown |
| Over 12 months | not shown |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — independent purity testing — as a table
| Answer | Reports |
|---|---|
| No, did not test | 36 |
| Yes — result matched the label | 9 |
| Yes — result did not match the label | not shown |
| Yes — unsure how to read the result | not shown |
| Don't know | not shown |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — side effects reported — as a table
| Answer | Reports |
|---|---|
| No side effects reported | 21 |
| Headache | not shown |
| Nausea | not shown |
| Vomiting | 6 |
| Dizziness or lightheadedness | not shown |
| Fatigue / low energy | not shown |
| Trouble sleeping | not shown |
| Vivid dreams | not shown |
| Flushing or feeling warm | 5 |
| Anxiety, restlessness or feeling wired | not shown |
| Low mood or irritability | not shown |
| Appetite change | not shown |
| Injection-site reaction (redness, itching, lump, bruising) | not shown |
| Nasal irritation, burning or sneezing | not shown |
| Effect faded with repeated use | not shown |
| No noticeable effect at all | not shown |
| New or darkening moles / freckles | not shown |
| Uneven skin darkening | not shown |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Melanotan I (afamelanotide) — still taking, stopped, or finished — as a table
| Answer | Reports |
|---|---|
| Still taking it | 23 |
| Finished a planned course | 9 |
| Stopped before I planned to | 18 |
| All | 50 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Gonadorelin — 47 reports · count, route and source
Gonadorelin — route — as a table
| Answer | Reports |
|---|---|
| Subcutaneous injection | 34 |
| Nasal spray / drops | 13 |
| All | 47 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Gonadorelin — source channel — as a table
| Answer | Reports |
|---|---|
| Retail pharmacy (brand product, prescription) | not shown |
| Compounding pharmacy | 8 |
| Telehealth or clinic (compounded) | 14 |
| Domestic research-chemical vendor | 11 |
| Overseas vendor | 8 |
| From another person | not shown |
| Don't know | not shown |
| Other (not listed) | not shown |
| All | 47 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Who contributed
Who contributed — age — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| 18–24 | 7.9% (7–9) · 119 |
| 25–34 | 25.1% (23–27) · 376 |
| 35–44 | 29.6% (27–32) · 444 |
| 45–54 | 17.6% (16–20) · 264 |
| 55–64 | 7.9% (7–9) · 119 |
| 65 or over | 2.5% (2–3) · 37 |
| Preferred not to say | 9.4% (8–11) · 141 |
| All | 1500 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Who contributed — sex — as a table
| Answer | Percent (95% interval) · reports |
|---|---|
| Female | 30.5% (28–33) · 457 |
| Male | 52.3% (50–55) · 784 |
| Intersex | 0.9% (1–2) · 13 |
| Non-binary | 1.8% (1–3) · 27 |
| Prefer not to say | 4.7% (4–6) · 70 |
| Preferred not to say | 9.9% (9–12) · 149 |
| All | 1500 |
Self-reported. Not evidence of effectiveness or safety. "Not shown" is a hidden cell: under 5 reports, or the one neighbour hidden with it.
Integrity log
Before each release, the coordinated-submission detector (public code: tools/detect.py) flags reports that contradict themselves and unusual bursts, such as many reports about one compound arriving on one day. Flagged reports stay in the committed log and leave the tables above the same way new reports enter them: in batches of at least five, so a single exclusion cannot be read off the difference between two releases. Until their batch they stay in the tables; the counts at the top leave them out at once.
No coordinated-submission pattern was identified in this period.
| Reason | This period | All time |
|---|---|---|
| malformed | 0 | 0 |
| implausible | 0 | 0 |
| duplicate-pattern | 0 | 0 |
| coordinated | 0 | 0 |
| test | 0 | 0 |
Flagged reports are listed by log position and reason in the exclusion list.